Sling Therapeutics closed a $123 million Series C led by Forbion, with participation from existing investor TPG Life Sciences Innovations and new investor Sectoral Asset Management. Proceeds will support the 130-participant global Phase III…
Nutshell Therapeutics, also known as Shanghai Yudao Biotechnology, announced a C1 financing of “tens of millions of U.S. dollars” co-led by CITIC Capital and Decheng Capital, with participation from Dachen Caizhi and a Wuxi…
GSK agreed to acquire full global rights to a preclinical trispecific T-cell engager from Chimagen Biosciences for multiple myeloma. Chimagen is eligible for an undisclosed upfront payment and development and commercial milestones bringing total…
Tyra priced an underwritten primary offering expected to raise approximately $400 million gross through common shares and nearly fully funded pre-funded warrants. The capital is earmarked for dabogratinib development across urothelial cancer and achondroplasia,…
GenScript Biotech conditionally placed 77.126 million new shares at HK$30.50 each, targeting net proceeds of approximately HK$2.327 billion. About 70% is intended for artificial-intelligence-driven drug-discovery capacity and infrastructure, 20% for related research, digital-workflow integration…
Lumiere Therapeutics, also known as Weiguang Gene in Chinese, completed a Pre-A financing of more than RMB100 million. Essential Capital and Huafang Capital co-led the round, joined by Yifeng Zhuohua, Junling Investment, the Guangzhou…
Solstice Oncology launched with a $225 million Series A led by RA Capital Management and joined by Canaan Partners, Forbion and other investors. The company was formed in February 2026 around porustobart, a clinical…
Encoded Therapeutics closed a $275 million Series F financing to fund pivotal development of ETX101 in SCN1A-positive Dravet syndrome, expand development through age 18, scale its internal GMP manufacturing operation and advance ETX301 toward…
TwoStep Therapeutics closed an oversubscribed $62.5 million Series A and received FDA clearance to begin first-in-human testing of TS-104, a peptide-drug conjugate designed to bind five tumor-associated integrins. The financing funds Phase I development,…
Schrödinger, New Enterprise Associates and RA Capital Management formed Tectora Therapeutics and closed a 55-million-dollar Series A financing. Schrödinger contributed two early-stage oral small-molecule programs, SDGR-4594 and SDGR-8139, for immune-mediated diseases and received an…
